Literature DB >> 25456868

Relation of physical activity to prevalence of nonalcoholic Fatty liver disease independent of cardiometabolic risk.

Ebenezer T Oni1, Rohan Kalathiya2, Ehimen C Aneni3, Seth S Martin4, Michael J Blaha4, Theodore Feldman3, Arthur S Agatston3, Roger S Blumenthal4, Raquel D Conceiçao5, Jose A M Carvalho5, Raul D Santos6, Khurram Nasir7.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and insulin resistance and has been linked with increased cardiovascular risk. Although physical activity (PA) and lifestyle modification are often recommended in patients at cardiovascular risk, the benefit across the cardiometabolic risk spectrum is unclear. We aimed to evaluate the relation of PA and NAFLD independent of metabolic syndrome (MS) or obesity. We evaluated 5,743 healthy Brazilian subjects (43 ± 10 years, 79% men) without clinical coronary heart disease from December 2008 to December 2010. NAFLD was diagnosed using ultrasounds, and self-reported PA was assessed using the International Physical Activity Questionnaire scale. In a multivariate logistic regression adjusted for cardiometabolic risk factors, we evaluated for an independent association of NAFLD and PA. In the total study population, NAFLD prevalence was 36% (n = 2,075), obesity 23% (1,300), and MS 20% (1,152). NAFLD was more prevalent in subjects with MS (74%) than those without (26%) and in those obese (73%) than in those nonobese (25%). Overall, 1,305 (23%) subjects reported low activity, 1,990 (35%) moderate activity, and 2,448 (42%) high activity. NAFLD prevalence was lower at higher levels of reported PA (low 45%, moderate 38%, and high 30%, p <0.001). After adjusting for risk factors, subjects with high activity had lower odds of having NAFLD. The favorable association was independent of obesity or MS. In conclusion, PA presents a dose-response association with NAFLD independent of the MS or obesity. Our results are compatible with the idea that benefits of PA are relevant to everyone regardless of cardiometabolic risk.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25456868     DOI: 10.1016/j.amjcard.2014.09.044

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

2.  Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation.

Authors:  Jihyun Kim; Da Young Lee; Se Eun Park; Cheol-Young Park; Won-Young Lee; Ki-Won Oh; Sung-Woo Park; Eun-Jung Rhee
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

Review 3.  Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review.

Authors:  Abdulrahman Ismaiel; Dan L Dumitraşcu
Journal:  Front Med (Lausanne)       Date:  2019-09-13

Review 4.  Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury.

Authors:  Hans-Theo Schon; Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-08-30       Impact factor: 5.810

Review 5.  Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.

Authors:  Óscar Soto-Angona; Gerard Anmella; María José Valdés-Florido; Nieves De Uribe-Viloria; Andre F Carvalho; Brenda W J H Penninx; Michael Berk
Journal:  BMC Med       Date:  2020-10-01       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.